Most antidepressants suppress rapid eye movement (REM) sleep, which is thought to be important to brain function, yet the resulting REM sleep restriction is well tolerated. This study investigated the impact of antidepressants with different mechanisms of action, such as selective serotonin reuptake inhibitors (SSRIs) and tricyclic antidepressants (TCA), on the regulation of REM sleep in rats. REM sleep was first demonstrated to be homeostatically regulated using 5, 8 and 10 h of REM-sleep specific restriction through EEG-triggered arousals, with an average of 91 ± 10% of lost REM sleep recovered following a 26e29 -hour recovery period.
Introduction
Most antidepressants inhibit rapid eye movement (REM) sleep in animals and humans. In particular, selective serotonin re-uptake inhibitors (SSRIs), such as citalopram and paroxetine, the mainstay of depression treatment, are potent inhibitors of REM sleep when administered acutely, sub-chronically or chronically (reviewed in Palagini et al., 2013) . Relatively few antidepressants offer psychiatric benefits without causing reductions in REM sleep (Sharpley and Cowen, 1995; Palagini et al., 2013) and extended courses of antidepressant treatment are well tolerated without the ill effects typically reported in experimental REM sleep deprivation paradigms (Vertes and Eastman, 2000; Siegel, 2001) .
The most common sleep-electroencephalography (EEG) markers of major depressive disorder (MDD) include shorter latency to the onset of REM sleep, increased REM sleep time and increased density of rapid eye movements during REM sleep; reduced sleep efficiency and reduced total sleep time slow wave sleep (Pillai et al., 2011) . Paradoxically, the changes in REM sleep parameters observed in MDD are similar to the effects seen following REM sleep restriction in humans and animals (Palagini et al., 2013; Kupfer et al., 1981; Coble et al., 1976; Lucidi et al., 1996) . The strong correlation between REM sleep inhibition and drug activity has led to the hypothesis that suppression of REM sleep may contribute to an antidepressant action (Vogel, 1983) . The antidepressant efficacy of REM-specific sleep restriction was tested by inducing awakenings upon the appearance of the first signs of REM sleep. REM sleep restriction alone was sufficient to improve depression and normalise the sleep architecture of patients . REM sleep is controlled by both circadian and homeostatic mechanisms (Brunner et al., 1990; Dijk and Czeisler, 1995; Wurts and Edgar, 2000) . REM sleep homeostasis can be tested through methods that selectively inhibit REM sleep manifestation via EEGdriven feedback methods, which provide a waking stimulus only if an animal enters REM sleep as determined in real-time from EEG and EMG measures (53 Wurts and Edgar, 2000; 126 Rechtschaffen and Bergmann, 1995) . Selective REM sleep deprivation leads to a progressive increase over time in attempts to enter REM sleep and REM sleep-enriched sleep following release from deprivation in both animals and humans (Vogel, 1975; Shea et al., 2008) . Homeostatic control of REM sleep has even been shown to persist in the absence of circadian control (Wurts and Edgar, 2000) . The conservation of REM sleep time suggests its importance in physiological processes and its homeostatic maintenance may be relevant to the antidepressant action of REM sleep restriction.
These observations raise the question: Is REM sleep inhibition caused by antidepressant therapeutics functionally equivalent to physiologically-induced forms of selective REM sleep deprivation? Antidepressants that suppress REM sleep potentially alter the neurochemical control mechanisms of REM sleep homeostasis. Many of the neurochemical circuits involved in controlling REM sleep onset and maintenance have been identified, with mutually inhibitory monoaminergic, GABAergic and glutamatergic systems (reviewed in Luppi et al., 2013) . The mechanisms underlying REM sleep homeostasis however remain largely unknown. In the current study the interaction between a pharmacological and physiologically induced REM sleep loss was examined.
The homeostatic response following REM sleep inhibition by antidepressants may differ to the homeostatic response caused by a physiological REM sleep restriction. To address this possibility, we paired REM specific sleep restriction with antidepressant treatments and closely evaluated interactions between the two mechanisms of REM sleep suppression. Two selective serotonin reuptake inhibitors (SSRIs), paroxetine and citalopram, and the tri-cyclic antidepressant (TCA) imipramine were tested alone and in the presence of increased REM sleep homeostatic pressure.
Methods

Subjects
All procedures were carried out in accordance with the UK Animals Scientific Procedures Act (1986) and associated guidelines, the European Communities Council Directive of 24 November 1986 (86/609/EEC) and passed the Lilly UK ethical review. In accordance with the principles of the 3Rs, all efforts were made to minimise animal suffering, to reduce the number of animals used, to refine procedures and utilise alternatives to in vivo techniques, if available. Male Wistar rats sourced from Charles River, Kent, UK were used as subjects for all experiments. At the time of surgery animals were approximately 70e80 days old and weighed 250e300 g.
Animal preparation and surgery
Rats were anesthetized (2% isoflurane in 100% oxygen) and surgically prepared with a cranial implant for chronic EEG and electromyogram (EMG) recordings. Body temperature and locomotor activities were monitored via a miniature transmitter (Minimitter PDT4000G, Philips Respironics, Bend, OR) Teflon-coated stainless steel wires positioned under the nuchal trapezoid muscles. The implant assembly was affixed to the skull by the combination of the EEG recording screws, cyanoacrylate applied between the hermetically sealed implant connector and skull, and dental acrylic. An analgesic (buprenorphine 0.05 mg/kg) was administered subcutaneously pre-operatively, at the end of the surgery day, and the morning of the first post-operative day. To provide additional pain relief, meloxicam 0.15 mg/kg was administered orally twice daily for 6 days post-surgery. The antibiotic cephalexin 20 mg/kg was administered orally 24 h prior to and immediately before surgery, and twice daily for 7 days after surgery.
Housing environment
After a 4-week recovery period, animals were housed individually in custom-designed sleep deprivation chambers for the duration of the experiment.
Sleep restriction chambers consisted of a rotatable cylinder (39.7 cm diameter by 32.1 cm length, 637.2 cm 2 floor space) constructed of plexiglass rods, positioned horizontally inside a plexiglass frame. Cranial implants were connected to ultra-low-torque slip-ring commutators (Hypnion, Inc., Lexington, MA, USA) by metal coil reinforced flexible cables, allowing unrestrained movements. EEG/EMG-signal based sleep restriction used real-time feedback of ongoing sleep/wake states to prevent sleep, similar to the methods described by (Wurts and Edgar, 2000) . The study was conducted in a sound-attenuated, light and temperature-controlled recording room, to control for sensory modalities known to affect sleep. Each cage was provided with an infrared light source and digital video camera to allow continuous remote visual monitoring. A 24-hr light-dark cycle (LD 12:12) was maintained throughout the study using fluorescent light to act as a zeitgeber (ZT). Light intensity averaged 35e40 lux at mid-level inside the cage. Food and water were available ad libitum and the ambient temperature was maintained at 21 ± 1 C with a relative humidity of approximately 50%.
Automated EEG/EMG data collection and sleep staging
Amplified EEG 10,000-fold (band-pass filtered 1e30 Hz: Grass Corp., Quincy, MA, USA) with an initial digitization rate of 400 Hz and amplified EMG (band-pass 10e100 Hz, RMS integration) were collected from the fixed electrodes. Concurrently, body temperature and locomotor activity were recorded. SCORE2004™, an automated sleep-wake and physiological monitoring system, was used to record and determine vigilance states, as previously described (Van Gelder et al., 1991; Seidel et al., 1995; Olive et al., 1998; Phillips et al., 2012) . Vigilance states were classified on-line as NREM sleep, REM sleep, wake, or theta-dominated wake, every 10 s, using EEG period and amplitude feature extraction and ranked membership algorithms. In addition to frequent on-line inspection of the EEG and EMG signals, quality control of the data was assured using a proprietary suite of programmes (SCOREVIEW™, Hypnion, Inc., Lexington, MA) that allowed data quality of all variables to be flexibly scrutinized at the level of (i) individual visual examination of raw EEG and EMG signals, (ii) individual hourly mean time series, and (iii) group mean time series, using a combination of graphical and statistical assessments. A fast Fourier transform was used to calculate the spectral EEG power in each 10-s epoch in 0.1 Hz bins. Telemetry measures (locomotor activity and body temperature) were not part of the SCORE vigilance-state determination algorithm; thus, sleep-scoring and telemetry data were concurrent but independent measures.
Dose selection and drug formulation
Citalopram (synthesized at Eli Lilly), paroxetine (Sigma Aldrich) and imipramine (Zerenex Ltd) were formulated in pH-adjusted methylcellulose 15 cP 0.25% vehicle. Compound was weighed using a Mettler Toledo AB104-S analytical balance then finely ground and suspended into vehicle. The doses of 10 mg/kg citalopram, 5 mg/kg paroxetine and 7 mg/kg imipramine were administered orally (PO).
The rationale for dose selection was as follows: A similar level of pharmacological REM inhibition to the 8-h EEG-driven feedback sleep restriction was selected for citalopram from a database of dose response data of compounds given at ZT-5 (data not shown). The doses of the remaining compounds were selected to match the level of REM sleep inhibition of citalopram. Statistical analysis was performed to determine the loss and recovery of sleep as a result of each treatment and evaluate potential interactions between REM sleep homeostasis and antidepressants. At least 7 days "washout" preceded and followed any treatment and examination of normal baseline activity relative to non-treated animals was performed prior to entry into the study.
REM sleep restriction protocol
Rats underwent at least 48 hrs of undisturbed baseline recording of sleep-wake patterns and before REM sleep restriction of 5, 8 or 10 h's duration starting ZT-0. Sleep and wake behaviours were determined automatically in real time using SCORE-2004™. Detection of REM sleep epochs by the SCORE2004™ program activates a motor to roll the cylindrical chamber around its axis for 8 s (265 of rotation at 11.5 cm/s), thereby initiating the righting reflex and waking the rat. The rotation caused a vestibular reflex, immediately awakening the rat.
In the studies combining REM sleep restriction with antidepressant administration, a REM sleep restriction period of 8 h was chosen. This level of REM sleep restriction showed a clear REM sleep deficit, followed by a rebound. In addition, 4-h of the light phase remained, during which the antidepressant drug treatments most actively suppressed REM sleep.
Study design and statistical analysis methods
The dose response to REM sleep restriction studies were conducted in distinct parallel groups, i.e., no animal was exposed to more than one REM sleep restriction. A total of 51 Wistar rats were used which at the start of the experiment were on average 131 ± 6 days old and weighing 487 ± 8.4 g (all values reported as mean þSEM). The magnitude of sleep loss relative to non-sleep restricted controls was calculated using a mixed model procedure with length of REM sleep restriction as a fixed effect. 24-h of the undisturbed baseline was used as a covariate to represent prior sleep history.
A within subject, full crossover, repeated measures study design was used for each REM sleep restriction and antidepressant combination experiment. A total of 53 Wistar rats, on average 138 ± 6 days old and weighing 484.3 ± 6.5 g at the start of each experiment, were randomly assigned to treatment groups. Prior to any treatment, animals were left undisturbed for 48-h to record a baseline from which drug effects could be evaluated. REM sleep restriction was performed between the hours of ZT-0 and ZT-8 and immediately following release from the REM sleep restriction, the rats were dosed orally with active compound or vehicle control (ZT-8, i.e., 8-h after lights on; Fig. 1 ). For drug administration, each animal was removed from its cage for about 60e90 s to be weighed and treated.
Statistical analyses and plotting were performed using the SAS (version 9.2, SAS Institute, Inc., Cary, NC) software package and SigmaPlot (version 12.5, Systat Software, Inc., San Jose California USA, www.sigmaplot.com). The effects of sleep restriction and drug were evaluated over the recording period as outlined in Fig. 1 . The following time periods were used: 0e8 h during the period of sleep restriction; 8e12 h of light immediately following drug administration when drug activity was maximal; and a final recovery phase between 12 and 36 h after the start of sleep restriction. Effects were evaluated using mixed model analysis with the magnitude of REM sleep restriction; drug treatment; and the interaction between the two factors as fixed effects with each subject acting as its own control. Hourly differences to baseline were evaluated using twotailed repeated measures ANOVA with a Bonferroni correction. Percentage deficits were calculated relative to control from the least squares means generated in the mixed model described. Recovery sleep was calculated from the differences generated in the mixed model between treatment groups. The percentage recovery is the proportion of additional sleep throughout the recovery period relative to the deficit induced by the REM sleep restriction. For example, if a deficit of 20 min is incurred and 15 min of this is recovered by the end of 48 h, a 75% recovery has been achieved.
Sleep recovery modelling
Accumulation of sleep was calculated after treatment, relative to the previous 24-h baseline. Bin ¼ 1 denotes the first 60 min posttreatment. Subsequent bins accumulate the change from baseline. Thus, positive slopes imply more time in the vigilance state than during the baseline e.g., recovery sleep, and a negative slope implies less time in the state e.g., sleep loss. Recovery sleep was modelled using an exponential decay process previously described (Stephenson et al., 2015) .
Three variables: Y 0, the initial sleep deficit; T 0, the response asymptote; and t, the response time constant were used to describe the model. Rspan, the quantity of recovered sleep is equivalent to Y 0 eT 0 . Analysis was performed using the Python 3.4 Scipy module (Jones et al., 2001 ) and the curve_fit function. Regressions were provided to initial estimates for Y 0 but not constrained as in the Stephenson et al. analysis (Stephenson et al., 2015) . The characteristic rate of rebound, t, is the exponential time constant of the response and is the time in hours to complete 1/e z 0.632 of Rspan).
Results
Sleep was evaluated over 72 h, including an undisturbed baseline period 24 h prior to treatment. During the baseline period, the rats displayed a clear 24-h (circadian) rhythm in their sleep that was consistent between treatment groups ( Fig. 2A and C) .
REM sleep restriction
EEG-driven feedback REM sleep restriction reduced the total amount of REM sleep from 5 to 10% to between 0 and 3% of the recording time across the range of restriction lengths. REM sleep time during the REM sleep restriction, which reflects number of attempts to enter REM sleep, increased linearly over the course of the restriction protocol ( Fig. 2A) . A mean REM sleep debt of 13.1 ± 1.6, 16.0 ± 2.2 and 37.3 ± 4.3 min was accumulated over control at 5, 8 and 10 h of REM sleep restriction respectively (Fig. 2B) , representing a reduction of 64 ± 9, 69 ± 8 and 60 ± 10% of REM sleep in the equivalent baseline light period. Release from REM restriction resulted in a prolonged elevation of REM sleep, in proportion to REM sleep loss. The elevation of REM sleep during the recovery phase compensated between 71% and 103% of REM sleep lost during the restriction, averaging 91 ± 10% across all studies. The total time in NREM sleep ( Fig. 2C and D) was not significantly affected relative to the non-sleep restricted control group, although in the first hour of sleep restriction a deficit in NREM sleep was elicited by the presence of the technicians. Interestingly, NREM bout sleep lengths were increasingly shortened as time in REM sleep restriction increased ( Supplementary Fig. 1 ).
The rate of REM sleep recovery was estimated using an exponential saturating function. Each REM sleep restriction length was Post-treatment measurements are broken down relative to the protocol and light-dark cycle to yield 5 distinct periods following: 0e8 h; 8e12 h; 12e24 h; 24e36 h and 26e48 h. Corresponding periods in the baseline were used in the analysis: À24 to À18 h; À18 to À12 h; À12 to 0 h; À24 to À12 h and À12 to À0 h. modelled independently (Table 1) and the model parameters representing the zero-cross deficit (Y 0 ), recovery rate constant (t) and asymptotic offset (T 0 ) were evaluated. REM sleep deprivation resulted in full recovery, resulting in asymptotic offsets (T 0 ) that were not significantly different to 0. Equivalent values for the recovery rate constant were also found at each dose level of REM sleep restriction; therefore increasing REM sleep deprivation only altered the initial deficit parameter.
Acute effects of antidepressants on REM sleep time under baseline conditions
The effects of citalopram, paroxetine and imipramine were evaluated under baseline conditions and following an 8 h REM sleep restriction using the experimental design shown in Fig. 1 . REM sleep time during the undisturbed baseline period 24 h prior to treatment was equivalent between treatment groups (data not shown).
Under baseline conditions, all doses of antidepressant given at ZT-8 inhibited REM sleep for the remaining 4 h of the light cycle (Figs. 3e5A). Citalopram and paroxetine both resulted in an 84 ± 8% reduction in REM sleep relative to vehicle controls (see Tables 2  and 3 for corresponding values in minutes of REM sleep), whereas imipramine inhibited REM sleep by 69 ± 9% reduction, relative to vehicle controls during the 8e12 h analysis period.
Following citalopram or paroxetine treatment, there was no significant recovery of REM sleep during the 12e48 h analysis time period (Figs. 3 and 4C) . Following citalopram administration, after 48 h a total of 96 ± 40% of the deficit in REM sleep remained (Table 2) . Paroxetine was tested to generalise findings to the selective serotonin reuptake inhibitor class and also showed no significant recovery, with a REM deficit of 105 ± 25% remaining after 48 h (Table 3 ). In contrast, imipramine, a tri-cyclic antidepressant, showed a full recovery of the REM deficit incurred during the 12e48 h analysis time period (Fig. 5B) , which accounted for 93 ± 28% of the REM sleep deficit (Table 4) .
REM sleep recovery was also modelled following pharmacological REM sleep inhibition (Table 1 ). The citalopram induced deficit was not fully compensated (T 0 ¼ À14.1 ± 0.7 min) but an equivalent recovery rate was estimated to REM sleep restriction (tau ¼ 5.4 ± 2.3 h). Paroxetine also showed a lack of REM sleep compensation (T 0 ¼ 20.3 ± 0.6 min) and a similar recovery rate constant (tau ¼ 3.7 ± 2.2 h). In comparison to the SSRI treatments, imipramine showed a full recovery (T 0 ¼ 3.5 ± 4.2) and significantly altered recovery rate constant relative to vehicle controls (tau ¼ 28.0 ± 11.2 h). Although the onset of the compensatory REM sleep period was clear following citalopram and paroxetine treatment, the inflection point (Y 0) following imipramine treatment was less so (Figs. 5C and D) . The onset point of recovery was systematically increased to evaluate the effect of the choice of inflection (Y 0 ) and shown to decrease from 28.0 ± 11.2 with choice of onset 4 h after treatment to 18.1 ± 6.2 with choice of onset 7 h after drug administration. Subsequent increases in the inflection point prevented the model from converging.
3.3. Acute effects of antidepressants on REM sleep time in the presence of increased REM sleep pressure Each experiment included a REM specific sleep restriction during the 8 h following lights on (ZT-0) with vehicle treatment as a placebo control. REM specific sleep restriction induced a 75 ± 10, 74 ± 9 and 67 ± 4% reduction in REM sleep relative to the non-sleep restricted control group in the citalopram, paroxetine and imipramine experiments respectively (Figs. 3e5B) . In each case, a rebound in REM sleep occurred and after 48 h a total of 115 ± 28, 73 ± 19, 86 ± 21% of the deficit in REM sleep was recovered (Tables 2e4).
The recovery rate constants for each of these studies were lower than those of the sleep restriction dose response, although these differences were not statistically significant (post-hoc t-test p ¼ 0.50, p ¼ 0.55, p ¼ 0.32 vs. 8 hr sleep restriction for the citalopram, paroxetine and imipramine study respectively).
In the presence of homeostatic REM sleep pressure caused by 8 h of REM sleep restriction prior to treatment all antidepressants elicited a similar deficit in REM sleep to acute administration without prior REM sleep restriction (Figs. 3e5B) . In the case of citalopram, a difference of only 2.7 ± 2.7 min (ANCOVA, p ¼ 0.33) was found between the two groups. Paroxetine also gave an equivalent reduction of REM sleep to the non-sleep restricted group, with a difference of only 0.1 ± 2.4 min (ANCOVA, p ¼ 0.96) during the 8e12 h analysis period. Finally, there was no significant difference between the REM inhibition of imipramine under control conditions and following REM sleep restriction (1.6 ± 2.7 min, ANCOVA, p ¼ 0.57).
The homeostatic response to the 8 h REM sleep restriction was still evident in each of the treatment groups regardless of which antidepressant was administered (Figs. 3e5D) . In the citalopram experiment, a total 115 ± 28 and 104 ± 26% of REM sleep deficit was recovered in the vehicle and citalopram treated groups respectively. During the period of REM sleep inhibition induced by citalopram, between 8 and 12 h after the onset of REM sleep restriction, REM sleep recovery from the sleep restriction continued with a recovery of 23 ± 7% of the deficit achieved during this time period. There were no significant interactions between citalopram and REM sleep restriction at any time point analysed. Table 1 Model parameters of the exponential recovery model of REM sleep. Y 0 is the deficit at 0 h (in minutes), T 0 is the final deficit (in minutes) and t is the recovery rate constant (in hours). Significance vs non-sleep restricted vehicle control was determined using ANOVA and is denoted by the following symbols: * 0.01 < p < 0.05; ** 0.001 < p < 0.01; ***p < 0.001.
REM sleep restriction length Y 0 T 0 t REM restriction 5 hr À25.2 ± 2.5*** À3.5 ± 3.8 6.5 ± 1.4 REM restriction 8 hr À42.6 ± 1.3*** À5.1 ± 3 8.0 ± 0.7 REM restriction 10 hr À46.7 ± 2.5*** À6 ± 2.7 6.3 ± 1.4 Citalopram À25.1 ± 1.3 À14.1 ± 0.7*** 5.4 ± 2.3 8 h REM restriction þ vehicle À26.9 ± 0.8*** 4.3 ± 0.8** 6.9 ± 1.1 8 h REM restriction þ citalopram À41.4 ± 0.8*** À12.2 ± 0.8*** 5.0 ± 1.0 Paroxetine À29.3 ± 3.7* À20.3 ± 0.6*** 3.7 ± 2.2 8 h REM restriction þ vehicle À29.9 ± 1.1* À7.8 ± 0.9* 7.0 ± 1.6 8 h REM restriction þ paroxetine À43.4 ± 0.7** À19.6 ± 0.7*** 9.1 ± 1.3 Imipramine À25.6 ± 8.1** 3.5 ± 4.2** 28.0 ± 11.2*** 8 h REM restriction þ vehicle À33.7 ± 0.8*** À3.13 ± 0.5 5.9 ± 1.0 8 h REM restriction þ imipramine À46.0 ± 7.0*** 0.21 ± 3.7 21.5 ± 6.0*** In the case of paroxetine, 91 ± 18 and 73 ± 19% respectively of the REM sleep lost from the REM sleep restriction was recovered in the paroxetine and vehicle treated groups respectively. Furthermore, during the 8e12 h analysis period, 25 ± 6 and 26 ± 7% of the REM sleep deficit induced by EEG-driven REM deprivation was recovered in both the paroxetine and vehicle treatment groups respectively. As with citalopram, there were no interactions between paroxetine and REM sleep restriction recovery.
Finally, imipramine also showed no significant difference in REM inhibition between control conditions and following REM sleep restriction. Imipramine inhibited REM sleep causing an additional deficit of 15.4 ± 2.0 min during the 8e12 h analysis period, a 52 ± 5% reduction, relative to vehicle controls. Additionally, imipramine did appear to interfere with REM sleep recovery from the REM sleep restriction (Table 4) . The absence of recovery sleep resulting from SSRI treatment was also still evident following REM sleep inhibition (Figs. 3 and 4E ). During the 12e48 h analysis time period there was no significant recovery in REM sleep as a result of paroxetine treatment. In contrast, recovery REM sleep following imipramine treatment combined additively with the recovery elicited by prior REM inhibition (Fig. 5E ). These results show that firstly REM sleep inhibition by the citalopram or paroxetine was unaltered by the presence of REM sleep pressure and secondly that citalopram had no impact upon the recovery of REM sleep following physiological REM restriction.
The recovery rates following the combination of both REM sleep restriction and citalopram administration remained similar to both citalopram and REM sleep restriction groups (Table 1 ). In contrast, paroxetine administered following REM sleep restriction, elicited a recovery rate that was greater than paroxetine alone but not different to that of the REM sleep restriction group. Imipramine had the clearest effect on the recovery rate constant. When administered following REM sleep restriction, imipramine further increased the REM deficit but complete recovery was still achieved albeit at a faster rate. Fig. 2A ). In this experiment, EEG-driven feedback REM sleep restriction caused a 10 ± 4% reduction of the NREM sleep prior to drug treatment. NREM sleep continuity was unaltered by citalopram treatment (Supplementary Fig. 2B ). Relative to the loss of NREM during the sleep restriction, a slight overshoot in the recovery of NREM sleep occurred in the vehicle treated group, but NREM sleep time was fully compensated in the citalopram treated group ( Supplementary  Fig. 2C) .
Paroxetine treatment at ZT-8 also did not alter NREM sleep time or continuity, either when dosed alone or following REM sleep restriction ( Supplementary Figs. 3A and B) . However, the recovery of lost NREM sleep up to 36 h post treatment, which was unaltered by the addition of paroxetine, showed full compensation of that lost during the REM-sleep restriction (Supplementary Fig. 3C ).
In addition to REM sleep inhibition, imipramine also reduced NREM sleep time ( Supplementary Fig. 4 ). Relative to vehicle controls, imipramine induced a total loss of 16.8 ± 3.0 min, which was 16.2 ± 2.9% of the equivalent baseline period, when dosed at ZT-8. Following REM sleep restriction this NREM sleep reduction did not occur, resulting in an interaction effect between the treatments (À14.6 ± 4.4, ANCOVA, p ¼ 0.002). Finally, recovery of lost NREM sleep resulting from imipramine was not recovered up to 36 h post treatment, whereas the loss resulting from REM sleep restriction was fully compensated.
Discussion
This study shows for the first time that the inhibition of manifest REM sleep by SSRI antidepressants occurs without augmenting or impairing compensatory REM sleep following EEG-driven physiological REM sleep restriction. In contrast, an equivalent level of REM inhibition induced by the TCA imipramine showed complete recovery adding to the compensatory response to prior REM sleep restriction.
Homeostatic recovery of REM sleep time following REM sleep restriction
The recovery of REM sleep across the range of 5, 8 and 10 h of REM sleep restrictions demonstrates the homeostatic regulation of , and the component of recovery from REM restriction (cRR) and imipramine (cIMI) attributed in the combination group; *p < 0.05; **p < 0.01; ***p < 0.001 ANCOVA.
Table 3
Summary statistics of REM restriction in combination with paroxetine. Measurement periods are split into pre-defined analysis periods. Comparison [2-1] is the quantity of REM in the paroxetine treated group relative to vehicle controls without REM sleep restriction. is the quantity of REM in the paroxetine treated group relative to vehicle controls in the REM sleep restricted condition. is the quantity of REM in the sleep deprived group relative to non-sleep deprived controls that received vehicle treatment. is the quantity of REM in the sleep deprived group relative to non-sleep deprived controls that received paroxetine. Statistical significance was determined by repeated measures ANCOVA, where baseline and date were included as covariates and a Tukey adjustment used. Significance is denoted by the following symbols: * 0.01 < p < 0.05; ** 0.001 < p < 0.01; ***p < 0.001.
Condition
Measurement REM sleep in rodents. The existence of REM sleep homeostasis, particularly in human studies, has been questioned due to a lack of significant recovery relative to the quantity of REM sleep (Endo et al., 1998; Werth et al., 2002) . However, in these studies recording time was often limited, in contrast to the present study. The current study found that, in male Wistar rats, REM sleep returned to a theoretical set point in accordance with previous studies in which the dynamics of this recovery were evaluated as an exponential decay process (Stephenson et al., 2015) . Overall these recovery data and the increased REM sleep attempts throughout the physiological REM sleep restriction period show that, under physiological conditions, REM sleep duration is tightly regulated through homeostatic mechanisms.
Acute suppression of time spent in REM sleep following antidepressant treatment
The loss of REM sleep induced by the three antidepressant was similar to that reported in previous studies in rats (Ivarsson et al., 2005) and humans (Wilson et al., 2004) . Acute REM sleep suppression induced by antidepressants was not significantly affected by prior physiological REM sleep restriction and we conclude that acute drug-induced suppression of REM sleep was independent of REM sleep pressure. A previous study that combined REM sleep restriction with the SSRI, escitalopram, also concluded that prior REM sleep restriction did not significantly alter the REM sleep inhibition effect of the compound (K atai et al., 2013) . However, REM sleep recovery was only observed over the first 3 h of the recovery period and significant REM sleep homeostatic recovery was unlikely to have occurred relative to the deficit of a 72 h sleep restriction.
Homeostatic recovery of REM sleep time following acute antidepressant treatment
We monitored REM sleep for at least 28 h following dosing, which is beyond the expected action of the drugs: citalopram and paroxetine have half-lives of approximately 3.7 h, and 2.2 h (unpublished Lilly data) respectively and imipramine has a half-life of 2.5 h (Dingell et al., 1964) in male Wistar rats. Administration of citalopram and paroxetine induced a REM sleep deficit that was not recovered over the following 28 h. Directly comparable data are not reported for humans, although in a single dose study of another SSRI (60 mg fluoxetine) in healthy volunteers, it was reported that despite an acute suppression of REM sleep in the first night, no significant rebound of REM sleep was observed for the following three nights (Feige et al., 2002) . In rats, Benington and Heller (1995) have also reported that ritanserin, a serotonin receptor antagonist, and quinuclydinyl benzilate (QNB), a cholinergic agonist, suppress REM sleep without a compensatory rebound.
Although a certain level of tolerance for lost REM sleep may exist following pharmacological treatment, equivalent physiological REM sleep inhibition showed a distinct rebound of REM sleep. A full recovery of the REM sleep deficit occurred following acute imipramine administration without prior REM sleep restriction, suggesting that in contrast to SSRIs, imipramine-induced REM sleep inhibition increases REM sleep homeostatic pressure, similar to REM sleep restriction. However, modelling of the recovery process following imipramine administration showed a significantly slower recovery rate relative to physiological REM sleep restriction.
Homeostatic recovery of REM sleep following the combination of selective REM sleep restriction and antidepressant treatment
Compensatory rebound following physiological sleep restriction remained similar even in the presence of SSRI antidepressant treatments. Furthermore, the additional loss of REM sleep induced by the SSRIs was not recovered throughout the recording period and the recovery rate constant remained unchanged despite the additional sleep pressure. Studies, using the 'flower pot' method to induce selective REM sleep deprivation, paired with es-citalopram treatment have previously been reported, although interactions between the treatments on REM sleep recovery were not extensively examined Prevot et al., 1996) . Based on our data, we propose that the mechanisms by which SSRIs inhibit REM sleep are not tracked by the REM sleep homeostatic process. In contrast, when imipramine was paired with prior REM sleep restriction, the recovery of both pharmacological and physiological REM sleep loss coincided, resulting in the recovery of all 
Pharmacological mechanisms of REM sleep regulation
It is likely that a homeostat, distinct from that controlling NREM sleep, is responsible for maintaining the amount of REM sleep over time. Throughout physiological REM sleep restriction a deficit in REM sleep is created via an arousal, which was followed by a rebound in REM sleep after release from the physiological REM sleep restriction. However, the mechanisms by which aspects of REM sleep are controlled are not well understood and no biological substrate for the homeostat has yet been identified.
In the present study, SSRI induced REM sleep loss showed no sign of recovery and the lack or presence of REM recovery was not dose-dependent (unpublished Lilly data). Rats treated with SSRIs awaken at the transition from NREM to REM (Kostyalik et al., 2014) but SSRIs may only mask the electrophysiological signs of REM sleep in rats, such as theta power and muscle atonia whilst its function may remain intact. However, the SSRI treatments did not reduce the recovery REM sleep induced by prior physiological REM sleep deprivation. If REM sleep were masked, then this would be expected to prevent the detection of both normal REM sleep and recovery REM sleep.
These results can be placed in the context of the hypothesis proposed by Franken that initiation and maintenance of REM sleep are controlled by separate processes (Franken, 2002) . SSRIs inhibit REM sleep by reducing NREM e REM transitions (Kostyalik et al., 2014) , without altering the lengths of NREM sleep bouts. Franken proposed that REM sleep initiation is a NREM sleep-dependent sensitization process whose level rises during NREM sleep episodes. The SSRIs did not alter NREM sleep bout lengths, suggesting that the sensitization process does not occur. However, why this is the case remains unknown. Imipramine by contrast extends NREM sleep bouts, which induces greater sensitization and reduces the opportunity for REM sleep. This leads to the subsequent increase in REM sleep during the recovery period. In the present study we have not explored to what extent effects on REM sleep may be accompanied by changes in EEG slow wave activity in NREM sleep, or attempts to enter REM sleep. Further exploratory analyses are warranted given the interactions between the sleep states.
Limitations
Circadian factors may greatly influence the effects of pharmacological treatments as many treatments target circadian gene products (Zhang et al., 2014) . In this study, the REM sleep inhibition is confounded to some degree by the timing of the light-dark cycle. There is significantly less REM sleep to inhibit during the dark phase which may mask the true extent of REM inhibition by the SSRIs. However, any REM sleep recovery would likely have been observed over the subsequent 28 h, which was often evident during the dark phase following physiological REM sleep restriction. Further work to examine how circadian rhythmicity and the REM sleep homeostat interact may provide clues to the mechanism of REM sleep regulation. In addition to these effects, limitations in the mathematical model of REM sleep recovery were apparent once REM sleep homeostasis was blocked or strongly attenuated. Without a significant recovery, the exponential function was a poor fit to the data, leading to large errors. Furthermore, the exponential recovery model may introduce systematic discrepancies between the fitted curve and the data, as observed in the REM sleep restriction recovery of the citalopram experiment between hours 4e6. Better models of sleep recovery should be flexible enough to cope with these situations. One potential model is a power law function that could reduce the impact of selecting the initial onset recovery time upon the estimated rate of recovery.
The present findings may be relevant to potential side effects and efficacy associated with pharmacological REM sleep restriction by antidepressant treatments. We hypothesise that SSRIs do not engage the REM sleep homeostatic mechanism, which may minimise the effects of lost REM sleep. In contrast, the TCA imipramine does engage the REM sleep homeostat in a similar way to EEGdriven feedback-REM sleep restriction, which may suggest mechanism of action -based differences in which antidepressants impact sleep and potentially produce their antidepressant efficacy.
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